Drugs / tefibazumab
tefibazumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00198289 | Apr 2005 → Jun 2006 | staphylococcus aureus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00198302 | ? → Feb 2005 | staphylococcus aureus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tefibazumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00198289 ↗ |
| Known as | Aurexis | “Aurexis® (tefibazumab)” NCT00198289 ↗ |
| Known as | INH-H2002 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108055 ↗ |
| Modality | Monoclonal antibody | “Aurexis is a humanized monoclonal antibody” NCT00198302 ↗ |
| Route | Intravenous | “receive one dose of Aurexis® intravenously on Study Day 1” NCT00198302 ↗ |